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Abstract 
Parkinson’s disease (PD) is a common neurodegenerative disorder caused by the progressive 
degeneration of the nigrostriatal dopaminergic pathway. The resulting loss of dopamine 
neurotransmission is responsible for the symptoms of the disease. Available treatments are 
initially successful in treating PD symptoms; however, their long-term use is associated with 
complications and they cannot stop the neurodegeneration. Current research aims at 
developing new therapies to halt/reverse the neurodegenerative process, rather than treating 
symptoms. Neurotrophic factors are proteins critical for maintenance and protection of 
neurones in the developing and adult brain. Several neurotrophic factors have been 
investigated for their protective effects on dopaminergic neurones. Here we review some of 
the most promising factors and provide an update on their status in clinical trials. 
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1. Parkinson’s disease 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, with an 
incidence of 1.5-2% in the population over 60 years of age, which increases significantly with 
advancing age. As life expectancy is significantly increasing in the Western world, the 
incidence of PD is steadily escalating. Consequently, the financial and economical burden of 
the treatment and care of PD patients is substantial and increasing [1]. Thus, research on the 
causes of this debilitating disease is critical, as is the development of new treatments.  
 
PD is caused by the progressive degeneration of the nigrostriatal (A9) dopaminergic pathway, 
which projects from the substantia nigra in the midbrain to the caudate-putamen (striatum) in 
the forebrain [2, 3]. The resulting loss of dopamine neurotransmission in the striatum causes 
the cardinal symptoms of the disease: tremor at rest, rigidity and bradykinesia. Approximately 
5% of PD cases are caused by heritable genetic mutations. The remaining cases are sporadic 
and of unknown origin, although many theories have been proposed to explain the cause of 
dopaminergic neuronal death which occurs in PD, such as environmental toxins, 
mitochondrial dysfunction with resulting oxidative stress, and inflammatory mechanisms [4, 
5]. 
 
The therapies presently available for PD are not effective in the long-term and cannot stop the 
ongoing neurodegeneration. The most commonly-used treatment is the dopamine precursor, 
levodopa, which replaces lost dopamine in the denervated striatum and relieves motor 
symptoms. Levodopa is generally administered in conjunction with an inhibitor of peripheral 
decarboxlyase (carbidopa, benserazide), which has the effect of enhancing the central activity 
of levodopa. Levodopa is initially successful, however about 50% of patients develop 
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complications within the first five years of treatment, primarily severe motor fluctuations and 
dyskinesias. Other drug treatments include inhibitors of the dopamine breakdown enzymes 
catechol-O-methyl-transferase (tolcapone, entacapone) or monoamine oxidase–B (selegiline, 
rasagiline), and dopamine receptor agonists (bromocriptine, pergolide, pramipexole, 
ropinirole). Surgical methods involving ablation of deep brain structures or deep brain 
stimulation have also been used with good success, but these procedures are not widely-
available or applicable for all patients. In summary, none of the current treatments provide 
safe and long-lasting relief from the symptoms and have little or no effect on the progression 
of the disease [1]. Current research is aimed at developing therapies that will halt the 
neurodegenerative process, rather than simply treat the symptoms. These include the use of 
antioxidants, anti-apoptotic agents, cell-based therapies and neuroprotective agents such as 
neurotrophic factors (NTF). 
 
2. Neurotrophic factors for dopaminergic neurones 
NTF are secreted proteins that play critical roles in the induction, specification, survival and 
maturation of developing neurones. Certain NTF also act in the adult brain, to support and 
protect mature neuronal populations. As PD is primarily caused by the degeneration of a 
single neuronal population, several factors have been investigated for their neurotrophic and 
protective effects on dopaminergic neurones. The goal of this therapeutic approach is to apply 
a factor(s) which can halt or reverse the progressive degeneration of nigrostriatal 
dopaminergic neurones, and which can be administered to patients in a safe, targeted and 
long-lasting manner. NTF that have selective effects on dopaminergic neurones represent 
good targets for this approach. These include glial cell line-derived neurotrophic factor 
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(GDNF), neurturin, growth/differentiation factor (GDF) 5, mesencephalic astrocyte-derived 
neurotrophic factor (MANF) and cerebral dopaminergic neurotrophic factor (CDNF). 
 
2.1 GDNF family of ligands (GFL) 
2.1.1 Effects of GDNF in vitro 
The GFL family is composed of four factors - GDNF, neurturin, persephin and artemin. 
GDNF, its prototypical member, was isolated from a glial cell line due to its neurotrophic 
effects on cultured dopaminergic neurones [6]. Subsequent studies have shown that it can also 
act on other neuronal types (see [7]). GDNF has been shown to induce the dopamine synthetic 
enzyme, tyrosine hydroxylase (TH), in fetal human and rat cortical cultures (Table 1) [8]. 
GDNF has been consistently shown to promote the survival and differentiation of 
dopaminergic neurones in vitro [6, 9, 10] and to protect these cells from the dopaminergic 
toxins, 1-methyl-4-phenylpyridinium ion (MPP+) and 6-hydroxydopamine (6-OHDA),[11-
13]. GDNF treatment has also been reported to reduce apoptosis in dopaminergic neurones 
cultured from embryonic rat [14, 15] and human [16] midbrain. GDNF can also protect 
cultured dopaminergic neurones from lipopolysaccharide-induced degeneration, a model of 
neuroinflammation [17]. Most of the above studies were conducted on embryonic day 14 
(E14) rat midbrain, the time point at which dopaminergic neurones are undergoing their 
terminal mitotic divisions and are beginning to differentiate. An in vitro study showed that 
GDNF can also support these neurones during their postnatal period of natural developmental 
death [18]. Midbrain cultures may contain dopaminergic neurones of two origins, the 
nigrostriatal pathway (A9), which degenerates in PD and the mesolimbic pathway (A10), 
which is largely spared in this disease. Differential effects of GDNF treatment on A9 andA10 
dopaminergic neurones in vitro have been reported, whereby a single dose of GDNF 
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selectively enhanced the survival of A9 cells, while repeated exposure to this factor only 
increased the survival of A10 cells [19].  
 
2.1.2 Effects of GDNF in vivo 
In normal adult rats, a single injection of GDNF into either the substantia nigra or striatum 
significantly increased the levels of dopamine and its metabolites in the striatum and nigra 
[20]. Several studies have reported neuroprotective and functional effects of GDNF in adult 
animal models of PD (see [21]). In one early study, repeated injections of recombinant rat 
GDNF protected against dopaminergic cell loss induced by transection of the adult rat medial 
forebrain bundle (MFB), the fibre bundle containing the dopaminergic projections from the 
substantia nigra to the striatum [22].  
 
The most widely-used laboratory model of PD involves unilateral injection of the selective 
dopaminergic toxin, 6-OHDA in the adult rat. This results in the degeneration of nigrostriatal 
dopaminergic neurones and consequent depletion of striatal dopamine transmission on one 
side of the brain. Stereotaxic injection of 6-OHDA into the MFB or substantia nigra induces a 
complete lesion of the nigrostriatal pathway, while intrastriatal injection induces progressive 
neurodegeneration. Several groups have examined the effects of intracerebral injection of 
recombinant GDNF in rats with 6-OHDA-lesions of the MFB. Injection of GDNF in or near 
the substantia nigra at four weeks after or just before a 6-OHDA lesion resulted in reduction 
of motor deficits, and preservation of nigral dopaminergic neurones and striatal dopamine 
release and uptake [23-25]. In adult rats with bilateral 6-OHDA lesions of the MFB, injection 
of high doses of GDNF into the lateral ventricles resulted in improved motor function and 
sparing of nigral dopaminergic neurones [26]. GDNF’s effects may be dependent on host age, 
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as one study found that young rats displayed significantly higher levels of neuroprotection 
than aged rats [27]. This may be relevant to clinical trials, where the age of the patient may 
determine the extent of neuroprotection that is achieveable with GDNF treatment. 
 
The intrastriatal lesion model has been used extensively since it is possible to administer the 
NTF while neurodegeneration is progressing. Administration of single or multiple doses of 
recombinant human GDNF near or in the substantia nigra starting at the day of, or the day 
before, a 6-OHDA-induced lesion, had protective effects on nigral dopaminergic cell bodies 
[28, 29] A series of four intrastriatal injections of GDNF was found to decrease drug-induced 
rotations and preserve nigrostriatal dopaminergic neurones in adult rats with 6-OHDA-
induced lesions [30]. Long-term rescue of nigrostriatal dopaminergic neurones from 6-OHDA 
lesions was reported after short-term GDNF treatment [31]. Long-term protection against 
rotational asymmetry, reductions in striatal dopamine levels and uptake, and death of nigral 
dopaminergic cell bodies induced by 6-OHDA lesions of the MFB was conferred by a single 
dose of GDNF, divided between the lateral ventricle and substantia nigra [32]. GDNF 
injections into the striatum one week after an intrastriatal 6-OHDA lesion resulted in re-
innervation of the striatum as well as recovery of motor function [33], indicating that the 
ability of intrastriatal GDNF injection to confer behavioural improvements may be due to its 
effects on the remaining striatal afferents in the partially-denervated striatum. 
 
For application to clinical studies, the optimal injection site for production of safe and 
effective results is obviously an important consideration. Some studies have directly 
compared the sites of administration of GDNF in 6-OHDA-lesioned rats. Kirik et al. found 
that intrastriatal GDNF delivery had protective effects on motor function and the integrity of 
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the nigrostriatal pathway, intranigral GDNF protected nigral cell bodies but not striatal 
innervation or motor function, while intraventricular GDNF had no significant effects [34]. 
Another study found that intraventricular infusion of GDNF starting two weeks after an 
intrastriatal lesion had protective effects on the integrity and function of the nigrostriatal 
pathway, which lasted for six weeks after cessation of GDNF infusion, whereas the effects of 
intrastriatal infusion stopped upon withdrawal of GDNF [35]. Another group found that 
intrastriatal infusion of a high dose of GDNF four weeks after an intrastriatal lesion induced 
restorative effects on motor behaviour and the integrity of dopaminergic neurones and their 
terminals [36]. Thus, the intrastriatal route of administration appears to be the most 
efficacious in this progressive model of PD. Sequential application of GDNF over the nigra 
for two weeks, followed by injections of GDNF into the striatum for three weeks, in rats with 
intrastriatal 6-OHDA lesions, protected nigral dopaminergic cell bodies but did not prevent 
striatal denervation or improve motor function [37]. This suggests that the motor 
improvements observed in the other studies were dependent on an ability of GDNF to induce 
reinnervation of the lesioned striatum, perhaps by stimulating axonal sprouting from the 
remaining dopaminergic neurones. Thus, once the axonal retraction to the level of the nigra 
has occurred, application of GDNF to the striatum appears to be ineffective. This is an 
important consideration for clinical studies, as it suggests that there is a window of 
opportunity in which GDNF application may be therapeutically effective, but that this factor 
may not be useful at advanced stages of the disease. 
 
In another commonly-used animal model of PD, N-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-treated adult mice, GDNF injected either before or one week after 
MPTP treatment, conferred significant protective or restorative effects, respectively [38].  
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Gash and colleagues showed that administration of recombinant GDNF in MPTP-treated 
rhesus monkeys induced motor recovery and protection of nigral dopaminergic neurones and 
their striatal projections [39]. Combined application of oral levodopa and 
intracerebroventricular GDNF resulted in significant behavioural improvements with reduced 
levodopa-induced side-effects, in MPTP-treated monkeys [40]. Another study found that 
intraventricular GDNF improved motor function and reduced levodopa-induced dyskinesias 
in this model [41]. Significant recovery of motor function for at least four months was 
reported in MPTP-treated monkeys that had received GDNF into the lateral ventricles [42], 
while intraventricular injections of GDNF were found to increase intrastriatal but not 
intranigral dopamine levels [43]. Infusion of GDNF into the putamen of MPTP-treated 
monkeys induced a gradual and significant reduction in parkinsonian symptoms [44]. This 
appeared to be a regenerative action, since GDNF was injected at three months after the 
MPTP lesion, when the nigrostriatal pathway had presumably undergone significant 
degeneration. Chronic intraputaminal administraion of GDNF in aged monkeys had a long-
lasting protective action on nigrostriatal dopaminergic neurones and on motor function, 
without any adverse side-effects [45].  
Neurotrophic proteins like GDNF are metabolised rapidly in the brain and thus single 
injections of this factor cannot confer permanent effects. Gene therapy approaches have been 
applied to achieve long-term and targeted delivery of GDNF to the injured nigrostriatal 
pathway. Adenoviral vector delivery of GDNF into or close to the substantia nigra [46, 47] or 
into the striatum [48, 49] of rats with intrastriatal 6-OHDA lesions resulted in significant 
motor improvements and protection of nigral dopaminergic neurones. Adenoviral-delivered 
GDNF induced behavioural and neuroprotective effects when injected into the substantia 
nigra, but not into the striatum, in rats that had intrastriatal 6-OHDA lesions [50]. In MPTP-
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treated mice, adenoviral vector-mediated GDNF delivery to the striatum prevented depletion 
of striatal dopamine levels [51]. A study which compared the effects of intrastriatal and 
perinigral injection of an adenoviral vector encoding GDNF found that, while both injection 
routes conferred protective effects on dopaminergic cell bodies in the nigra, only the 
intrastriatal route reduced motor deficits, in rats with intrastriatal 6-OHDA lesions [52]. 
 
Another vector system, based on adeno-associated virus 2 (AAV2), has also shown efficacy 
in animal models of PD. Mandel and co-workers reported significant protective effects on the 
nigrostriatal pathway and its functioning, in adult rats with intrastriatal 6-OHDA lesions, 
following intranigral injection of AAV2-GDNF either three weeks before [47] or just after the 
lesion [53]. AAV2-mediated delivery of GDNF to the striatum, but not to the substantia nigra, 
induced gradual behavioural recovery and regeneration of the 6-OHDA-lesioned nigrostriatal 
system in adult rats [34]. AAV2 vectors have the advantage over adenoviral vectors in that 
they can integrate and stably express their transgene product in non-dividing cells such as 
neurons. Also, they are relatively safe as there is little or no host immune response due to the 
absence of viral genes in these vectors. Their disadvantage is that they can only deliver gene 
constructs of relatively small size compared to adenoviral vectors. Furthermore, there is a 
delay before the transgene is expressed following intracerebral injection of an AAV2 vector. 
 
A third type of vector system, based on lentiviruses, has also been used to deliver GDNF in 
PD animal models, with promising results. Lentiviral vectors have the capacity to deliver 
large transgenes and they can integrate efficiently into non-dividing cells. Delivery of the 
human GDNF gene using lentiviral vectors in MPTP-lesioned and aged rhesus monkeys 
achieved long-term gene expression and significant functional benefits [54]. Kordower and 
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colleagues administered lentiviral-GDNF to the striatum and substantia nigra of nonlesioned 
aged monkeys and MPTP-treated young monkeys and found extensive expression of GDNF 
in all of the brains. Lentiviral-delivered GDNF reversed motor deficits in the aged monkeys 
and prevented nigrostriatal degeneration and the development of functional deficits in the 
MPTP-lesioned animals. Another study used a lentiviral vector to achieve long-term delivery 
of GDNF to the striatum and substantia nigra of aged rhesus monkeys, and found that this 
treatment conferred significant protective effects on the functioning and integrity of the 
nigrostriatal pathway [55]. Lentiviral delivery of GDNF was also found to increase the 
number of intrinsic dopaminergic neurones in the primate striatum [56]. Lentiviral-mediated 
delivery is very effective but there are concerns about its safety and these will have to be 
addressed before clinical application of this system is feasible.  
 
Another avenue of exploration is the co-administration of NTF with neuronal transplants in 
cell replacement therapy approaches to PD. Transplantation of embryonic midbrain tissue is a 
promising and successful therapy for PD, but is limited by the poor survival of the 
transplanted dopaminergic neurones (see [57]). GDNF has been shown to improve the 
survival and integration of grafted embryonic dopaminergic neurones in animal models of 
PD. Rosenblad and colleagues reported that repeated injections of this factor adjacent to 
embryonic rat ventral midbrain grafts in the 6-OHDA-lesioned rat striatum improved the 
survival of the grafted dopaminergic cells and induced earlier recovery of motor function than 
untreated grafts [58]. Improvements in the survival of grafted dopaminergic neurones and 
their integration into the host striatum were also reported after pre-incubation of the grafts 
with GDNF [59-62]. Injection of GDNF along the nigrostriatal tract stimulated the outgrowth 
of dopaminergic fibres from intranigral grafts towards the striatum [63-65]. Enhancement of 
complex motor functions, as well as improved graft survival, were found in 6-OHDA-
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lesioned rats that had received GDNF-pretreated grafts [66]. GDNF pre-treatment has also 
been used to promote the survival of human fetal midbrain tissue, when grafted into two PD 
patients [67]. These patients displayed a large increase in fluorodopa uptake after one year, an 
index of striatal dopaminergic transmission, as measured by positron emission tomography 
(PET).  
 
Ex vivo gene therapy approaches have been applied in attempts to extend the effects of 
exogenous GDNF, which is rapidly metabolised in vivo. Genetically-modified embryonic rat 
midbrain cells which over-express GDNF have been found to induce earlier functional 
recovery in 6-OHDA-lesioned rats than control grafts [68]. GDNF-overexpressing rat neural 
precursor cells also significantly increased the survival of co-grafted embryonic dopaminergic 
neurones [69]. Human neural progenitor cells have been used to deliver GDNF, which 
conferred protective effects on the lesioned nigrostriatal pathway in adult rats [70]. This 
cellular delivery system, which allows the release of GDNF under an inducible promoter, has 
also been found to provide GDNF to the aged monkey brain for at least three months [70]. 
Encapsulation technology involves enclosing cells within a semi-permeable membrane 
composed of polymer fibres, which allows outward diffusion of any proteins secreted by the 
cells, while preventing the cells from proliferating extensively and forming tumours. 
Intrastriatal grafting of an encapsulated GDNF-expressing human (BHK) cell line has been 
shown to confer neuroprotective and restorative effects in 6-OHDA-lesioned rats [71, 72], 
particularly when the GDNF-expressing cells are implanted at an early stage of the disease 
progression [73]. Encapsulated human fibroblasts genetically engineered to overexpress 
GDNF were found to exert regenerative effects when implanted into the rat striatum one week 
after an intrastriatal 6-OHDA lesion [74]. Although the cells were removed after six weeks, 
the regenerative effects on motor function and on nigral dopaminergic neurones were evident 
14 
for a further seven weeks, indicating that transient delivery of GDNF was sufficient to confer 
sustained effects. In MPTP-treated primates, encapsulated GDNF-expressing cells induced 
transient motor improvements and increases in striatal dopamine uptake, without any adverse 
side-effects [75]. Encapsulated cells expressing GDNF have also been applied in combination 
with embryonic rat brain grafts in 6-OHDA-lesioned rats, and were found to improve the 
survival of the grafted dopaminergic neurones and their functional effects [76]. Encapsulated 
cell technology may have great potential for future clinical studies, should the promising 
effects found in these animal studies be extended to show long-term and safe delivery of 
appropriate doses of neurotrophic proteins (see [77]).  
 
2.1.3 Effects of neurturin in vitro  
A second member of the GFL family, neurturin, was identified for its survival-promoting 
effects on sympathetic neurones [78]. It was found to promote the survival of developing and 
mature dopaminergic neurones in vitro, These effects were similar in strength to those of 
GDNF [79, 80]. Neurturin is expressed in the ventral midbrain and striatum during 
development [80].  
 
2.1.4 Effects of neurturin in vivo 
Neurturin has been found to exert protective and functional effects on dopaminergic 
nigrostriatal neurones after 6-OHDA lesions of the adult rat MFB [79, 80] or striatum [81, 82] 
and after axotomy of the adult rat MFB [83]. The study by Rosenblad and colleagues directly 
compared the effects of neurturin with those of GDNF in the striatal 6-OHDA lesion model. 
They found that neurturin was less efficacious than GDNF after intrastriatal and especially 
after intraventricular delivery, which may reflect poor solubility of neurturin in vivo [82]. 
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Another study showed that delivery of neurturin into the cerebral ventricles of adult rats using 
mini-pumps resulted in an increase in striatal dopamine levels [84]. A recent study reported 
that intranigral injection of recombinant neurturin induced increases in striatal dopamine 
release, which were similar in magnitude to those induced by intranigral injection of 
recombinant GDNF [85]. Intracerebral delivery of recombinant neurturin has also been found 
to protect nigrostriatal dopaminergic neurones and induce improvements in motor function in 
MPTP-treated monkeys [86, 87]. Co-administration with recombinant neurturin protein has 
been reported to improve the survival of fetal rat dopaminergic neurones after intrastriatal 
grafting into 6-OHDA-lesioned adult rats [88]. 
 
Lentiviral gene delivery to the striatum of 6-OHDA-lesioned adult rats of a modified 
neurturin construct, which had the pro-region deleted and replaced with an immunoglobulin 
heavy-chain signal peptide, had protective effects on the nigrostriatal pathway [89]. Sustained 
functional recovery, with minimal side-effects, was achieved following stereotaxic injection 
of an AAV2–based vector encoding the human neurturin gene, in MPTP-treated monkeys 
[90] and 6-OHDA-lesioned rats [91]. Stable expression of neurturin using this AAV2 delivery 
system was achieved for at least a year in rats [92]. Kordower and colleagues showed that, ten 
months after injection of AAV2-neurturin into the striatum and substantia nigra, MPTP-
treated parkinsonian monkeys displayed a large reduction in the intensity of their motor 
symptoms compared to buffer-injected animals. This functional recovery was accompanied 
by significant preservation of dopaminergic neurones [90]. A study using the same expression 
system in 6-OHDA-lesioned adult rats found long-term neurturin expression in the striatum 
and dose-dependant protective effects on the nigrostriatal dopaminergic neurones for at least 
ten months [91]. Similar results were found after application of this system in aged monkeys 
and no adverse effects were recorded in this study after thorough toxicological testing [93]. A 
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further study by this group found that the expression of neurturin using this system could be 
sustained for a year in rhesus monkeys, as could its therapeutic effects [94]. Unlike the case 
with GDNF, no antibodies to neurturin or no pathological abnormalities were detected after 
AAV2-delivery in primates [95]. 
 
2.1.5 Effects of persephin and artemin in vitro and in vivo 
Persephin, a third member of the GFL family, has also been found to exert neurotrophic 
effects on midbrain dopaminergic neurones in vitro [96] and in vivo [97]. This factor also has 
trophic effects on motor neurones [96] and has not been extensively investigated for its 
clinical potential in PD. The fourth member of the GFL family, artemin, has survival-
promoting effects on dopaminergic neurones in culture [98] and in vivo [99], and also has 
potent actions on sensory neurones of the dorsal root ganglia [98]. Like persephin, artemin 
has not progressed into clinical trials for PD; however it has been tested as a therapeutic for 
neuropathy [100].  
 
2.2 GDF5 
GDF5, a member of the Transforming Growth Factor β superfamily of proteins, is also being 
investigated for its therapeutic potential in PD. GDF5 is related to the Bone Morphogenetic 
Proteins, which are involved in diverse physiological functions, including the development of 
the nervous system, where they play roles in early CNS patterning as well as in neural cell 
fate determination, differentiation, and survival (see [101]).  
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GDF5 mRNA and protein expression have been found in the embryonic, neonatal and adult 
rat brain including the striatum and midbrain [102-104]. GDF5 protein expression in the rat 
brain peaks at E14, the time at which dopaminergic neurones in the developing midbrain are 
undergoing terminal differentiation [103]. 
 
2.2.1 Effects of GDF5 in vitro  
On embryonic rat dopaminergic neurones in vitro, GDF5 has selective trophic actions which 
are comparable to those of GDNF. Application of GDF5 promotes the survival of 
dopaminergic neurones in embryonic rat midbrain cultures and protects them against the 
dopaminergic neurotoxin MPP+ [102] and against free radical-induced damage [105]. 
Application of recombinant human GDF5 induced a dramatic increase in the number of 
dopaminergic neurones in cultures of embryonic rat midbrain [106]. This study found that the 
effects of GDF5 may be dependent on BMPR1b, since application of GDF5 at the time of 
plating, when BMPR1b is expressed, increases dopaminergic neuronal number, but 
application after six days in vitro, when this receptor is no longer expressed, had no effect. 
GDF5 treatment also induced morphological changes in cultured embryonic rat dopaminergic 
neurones, stimulating neurite outgrowth and branching [106, 107]. Clayton and Sullivan 
found that the effects of GDF5 were much greater when cultures were prepared from the 
lateral part of the developing midbrain. Furthermore, the BMPR1b receptor was expressed at 
higher levels in the lateral than in the medial region, suggesting that GDF5 acts through this 
receptor to increase dopaminergic neuronal number. Combined application of GDF5 and 
GDNF have been shown to have additive neurotrophic effects on cultured embryonic rat 
dopaminergic neurones, indicating that these two factors may act on separate subpopulations 
of cells [108].  
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2.2.2 Effects of GDF5 in vivo 
Studies have shown that GDF5 can protect and restore adult rat nigrostriatal dopaminergic 
neurones in 6-OHDA–lesioned animals. The first such study reported that intracerebral 
injection of recombinant human GDF5 just above the substantia nigra and into the lateral 
ventricles produced improvements in motor function, protected nigral dopaminergic neurones 
and their striatal terminals, and preserved striatal levels of dopamine, its metabolites and its 
uptake, in rats with 6-OHDA lesions of the MFB [109]. A follow-up study compared three 
injection sites and found that application of GDF5 into either the striatum or substantia nigra, 
but not into the lateral ventricle, produced optimal neuroprotective effects [110]. Delayed 
administration of recombinant human GDF5 at one or two weeks after an intrastriatal 6-
OHDA lesion resulted in significant improvements in motor behaviour, but only the one-week 
injection regimen induced protection of nigral dopaminergic cell bodies, whereas there was 
no significant rescue of striatal dopaminergic terminals after either time-point of treatment 
[111]. This indicates that there is a window of time at which the degenerating nigrostriatal 
pathway can be rescued by exogenous trophic factors, which has relevance to clinical studies, 
as such therapies may only be effective at earlier stages of the disease. GDF5 has also been 
reported to improve the survival and function of grafted dopaminergic neurones to the same 
extent as GDNF [61]. This study found that pre-incubation of embryonic rat midbrain tissue 
in GDF5 or GDNF produced significant improvements in cell survival after intrastriatal 
grafting in 6-OHDA-lesioned rats. Furthermore, GDF5-treated grafts conferred significant 
motor improvements and preservation of nigral dopaminergic neurones and their striatal 
terminals in 6-OHDA-lesioned rats, to at least the same extent as GDNF-treated grafts [61]. 
Each of these in vivo studies involved infusion of recombinant GDF5 protein, which can only 
be effective for a limited time due to its being metabolised in the brain. Future studies will 
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examine alternative administration methods, such as viral vector-mediated delivery or the use 
of encapsulated cell technology. One recent study reported that GDF5-over-expressing 
embryonic rat midbrain transplants survived well in the 6-OHDA-lesioned adult rat striatum 
and had significant effects to improve motor behaviour in these animals [112]. 
 
2.3 MANF and CDNF 
2.3.1 Effects of MANF and CDNF in vitro 
MANF and CDNF are members of a recently-described family of evolutionarily-conserved 
proteins which are secreted from glial cells and have potent effects on dopaminergic neurones 
(see [113]). CDNF mRNA and protein have been found in both developing and adult mouse 
striatum and substantia nigra, suggesting that this factor may provide trophic support to 
mature dopaminergic neuronal cell bodies and their terminals, as well play a role in the 
development of these cells [114]. CDNF is a paralogue of MANF, which was originally 
isolated from a rat mesencephalic astrocyte cell line and found to have selective trophic 
effects on dopaminergic neurones in vitro [115]. Polymorphisms in CDNF have recently been 
linked to an early-onset form of PD [116]. Like CDNF, MANF is expressed in the rodent 
nigrostriatal system during the early postnatal period, as well as in the adult [117]. The 
Drosophila homologue of MANF, DmMANF, is essential for the maintenance and function of 
dopaminergic neurones [118]. Although the receptors for MANF and CDNF have yet to be 
identified, it appears that they may act by a different mechanism to the GFL family members 
to exert their neurotrophic effects on dopaminergic neurones. It is possible that at least part of 
the action of MANF is via inhibition of endoplasmic reticulum (ER) stress-induced neuronal 
cell death [113, 119]. Overexpression of MANF has recently been shown to block apoptotic 
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cell death in sympathetic neurones cultured from the neonatal mouse superior cervical 
ganglion [120], supporting an intracellular mechanism of action.  
 
2.3.2 Effects of MANF / CDNF in vivo 
Intracerebral injection of recombinant human CDNF or MANF has been reported to have 
potent protective and restorative effects on the 6-OHDA-lesioned adult rat nigrostriatal 
pathway [114]. Each of these studies reported motor recovery and preservation of 
dopaminergic nigral cell bodies and their terminals in the striatum, conferred by intrastriatal 
injection of the NTF six hours before or four weeks after intrastriatal injection of 6-OHDA. 
The same group recently reported that intrastriatal infusion of CDNF via mini-pumps for two 
weeks, beginning at two weeks after an intrastriatal 6-OHDA lesion, was able to confer motor 
improvements and partially protect dopaminergic nigral cell bodies and their striatal terminals 
[121]. It is interesting that MANF appears to be transported through the brain in a different 
manner to that of GDNF, as radiolabelled MANF is transported to the cortex after intrastriatal 
injection [119], while labelled GDNF is retrogradely transported to the substantia nigra [122, 
123], as is labelled CDNF [121]. 
 
3. Dopaminergic neurotrophic factors in clinical trials  
3.1 GDNF in clinical trials 
The potent and reproducible effects of GDNF in animal models led to the initiation of clinical 
trials in PD patients. The clinical application of NTF is hampered by the fact that these 
proteins do not cross the blood-brain barrier, and are rapidly degraded in vivo. The need for 
direct intracerebral delivery of NTF may increase the level of complications in patients. The 
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first clinical trial was a randomised controlled trial involving 50 patients, and used 
intraventricular delivery of recombinant human GDNF (r-metHuGDNF, liatermin, 
manufactured by Amgen) or placebo [124]. This study reported no significant benefits of 
GDNF treatment over the placebo, probably because GDNF did not reach the striatum in 
sufficient amounts. In addition, troublesome side-effects were observed, including pain, 
depression, appetite loss and l’Hermitte’s sign [124, 125], and these may have been due to the 
intraventricular delivery (Table 2). 
 
Since intraventricular delivery did not achieve GDNF delivery to the striatum, subsequent 
trials used direct administration to brain parenchyma using a catheter system. Promising 
results emerged from two open-label trials, which used intraputaminal infusion of 
recombinant GDNF [126-129]. These trials both reported improvements in the patients’ motor 
symptoms and in activities of daily living, without any serious side-effects. Gill and 
colleagues demonstrated that direct uni- or bilateral intraputaminal infusion of GDNF had 
long-lasting benefits in five patients suffering from advanced PD. After 24 months of 
treatment, all patients reported complete absence of akinesia and a significant reduction in the 
duration of dyskinetic episodes. Motor dysfunction was significantly reduced in both on- and 
off-medication phases compared to pre-treatment levels [128]. The second study, by Slevin 
and co-workers, used unilateral intraputamenal infusion of escalating doses of GDNF in ten 
patients with advanced PD and reported similar results, showing bilateral motor 
improvements after 24 weeks [129]. In both studies, the only consistent adverse effect was a 
mild l’Hermitte’s sign. Improvements in dopamine storage were detected in the regions 
surrounding the catheter which was used for infusion of GDNF [126, 127].  
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These two studies demonstrated the feasibility and sustainability of GDNF treatment by 
intraputaminal infusion. However, a subsequent randomised placebo-controlled trial, 
involving 34 patients (17 received GDNF and 17 received placebo), reported no significant 
motor improvements in PD patients [124, 130]. After six months of bilateral intraputaminal 
infusion of recombinant GDNF, there were no significant differences between the motor 
scores of the unified Parkinson’s disease rating scale (UPDRS) in patients that had received 
GDNF and in those that had received a placebo. Furthermore, safety concerns were raised, 
since approximately 10% of the GDNF-treated patients developed antibodies against the 
peptide, which could potentially counteract the therapeutic benefits [131]. A similar 
proportion of patients who had participated in the two open-label trials also developed 
antibodies to GDNF [129, 130]. PET studies showed a significant increase in 18F-dopa intake 
in the GDNF-infused patients compared to the placebo group, demonstrating a functional 
effect of GDNF infusion, although this did not translate into significant motor improvements 
[130]. The discrepancies between the open–label and placebo-controlled trials may have been 
due to variations in patient selection, as well as to a placebo effect. Optimisation of surgical 
methodologies, catheter design and positioning, drug dosage and diffusion, and patient 
selection will be necessary for any future GDNF clinical studies. The development of 
inexplicable cerebellar pathology in a primate model of PD after administration of a high dose 
of GDNF raised a further safety issue [132]. This resulted in a controversial decision by 
Amgen to cease all clinical trials using GDNF (see [133-135]). A recent study paved the way 
for future clinical trials by investigating GDNF distribution in the non-human primate brain 
following AAV2-mediated intraputaminal delivery [136]. It appears to be generally accepted 
that GDNF therapy for PD requires further development in pre-clinical trials and it is probable 
that alternative methodologies, such as viral vector-mediated expression, may prove to be 
more effective for achieving long-term and targeted GDNF delivery (see [137]).  
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3.2 Neurturin in clinical trials 
Based on the promising results found in animal studies using AAV2-mediated gene transfer 
of neurturin (CERE-120), an open-label phase 1 clinical trial was initiated in PD patients by 
the company Ceregene [138]. Twelve patients, each suffering from advanced PD, received 
bilateral intraputaminal injections of AAV2-neurturin (at one of two doses) and were 
followed for twelve months. Results showed that neurturin-treated patients displayed 
reductions in their off-medication UPDRS score, decreases in the time spent in the ‘off’ 
period and reductions in dyskinesias, without any adverse side-effects [138]. However, a 
subsequent double-blind phase 2 trial, which involved 58 PD patients, was reported to have 
failed. In this trial, intraputaminal AAV2-neurturin did not have superior effects on motor 
function than sham surgery, when assessed after twelve months, and only modest benefits 
were recorded after eighteen months. Serious adverse side-effects were reported in about a 
third of the neurturin-treated patients [139]. Ceregene began to recruit PD patients for a new 
double-blind trial using AAV2-neurturin in September 2010 
(www.ceregene.com/press_101910.asp). This multi-centre phase 2 trial will involve about 52 
patients, half of whom will receive intraputaminal AAV2-neurturin and half of whom will 
receive sham surgery. It is hoped that a new dosing regimen, designed to maximise the 
delivery of the neurturin gene throughout the degenerating nigrostriatal system, will be the 
key to a promising outcome from this trial. This hypothesis is based on a post mortem 
analysis on the brains of some of the patients who had received AAV2-neurturin (and who 
had died of unrelated causes), which found that neurturin had been retrogradely transported 
from the intraputaminal injection site to the substantia nigra [140]. The company 
subsequently administered AAV2-neurturin to both the substantia nigra and the striatum of 
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six PD patients and, based on analysis of the safety data from these six patients, are now 
recruiting patients for the second phase of this trial.  
 
4. Conclusion 
Despite the recent disappointing results in clinical trials with GDNF and neurturin, there 
remains an optimism that NTF will prove to be useful in PD therapy (see [7]). Optimisation of 
delivery methods is needed and vital information is being gleaned in this respect from studies 
in animal models, such as grafting of encapsulated cells expressing NTF and viral-mediated 
NTF delivery. It is likely that NTF will be most applicable in the early stages of the disease, 
to provide neuroprotection to the remaining nigrostriatal dopaminergic neurones before 
extensive neuronal loss has occurred. For future clinical trials, optimisation of surgical and 
infusion protocols, as well as careful patient selection, will be critical to advance this 
promising therapeutic approach. Animal studies have provided signs that NTF therapy may be 
more applicable in young patients than in old, and also that patients with earlier, less severe, 
disease stages may be more responsive to this type of therapy than those at advanced disease 
stages.  
 
Researchers are currently investigating the use of stem or progenitor cells as a possible 
alternative to freshly-dissected embryonic midbrain for transplantation in PD patients. The 
use of such cells would alleviate some of the ethical and practical concerns associated with 
the use of fresh embryonic tissue. It is likely that NTF could be used to improve stem cell 
therapy for PD, both to enhance the survival of transplanted dopaminergic precursor cells, and 
to induce a dopaminergic cell fate in unspecified progenitors. 
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In conclusion, much research still remains to be conducted in the area of NTF therapy for PD. 
In the case of those factors which have been tested in clinical trials (GDNF and neurturin) 
optimisation of the surgical delivery procedures and patient selection will be critical to the 
ongoing development of this therapeutic approach. Exploration of novel delivery 
mechanisms, such as viral vector-mediated delivery and cell encapsulation, which has been 
tested in animal models of PD to deliver GDNF, will be critical. More information is needed 
about factors such as GDF5 and CDNF, which have shown promise in preclinical models of 
PD. Knowledge of the receptors and signal transduction pathways that are involved in the 
neurotrophic and protective effects of these factors will aid the future development of safe and 
targeted therapeutics. 
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Table 1: Effects of GDNF on dopaminergic neurones in vitro 
 
Effect Reference 
Increases Tyrosine Hydroxylase expression [8] 
Promotes survival of mesencephalic cultures [6, 9] 
Promotes morphological differentiation [10] 
Protects from MPP+ neurotoxicity [12, 13] 
Protects from 6-OHDA neurotoxicity [11] 
Decreases apoptosis [14, 15, 16] 
Protects from LPS neurotoxicity [17] 
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Table 2: Neurotrophic factors in clinical trials 
 
Neurotrophic 
factor 
rh-methionyl-
GDNF 
rh-methionyl-
GDNF 
rh-methionyl-
GDNF 
rh-methionyl-
GDNF 
AAV2-
NRTN 
AAV2-
NRTN 
Trial type MC,R,DB,PC Open-label Open-label MC,R,DB,PC Open-label MC, DB, SSC 
Delivery 
Site ICV IPu IPu IPu IPu IPu 
No. Patients 50 5 10 33 12 58 
Age / 
Duration of 
disease 
(years) 
58±8 / 11±6 54.2±6 / 19±9.8 
57.9±9.3 / 
8.7±3.6 
56±7.2 / 
9.7±3.9 57±8 / 11±3 60±7 / 10±3 
Benefits No Yes Yes No Yes No 
Side-effects 
LS, 
Nausea, 
Anorexia 
LS LS, Headaches 
LS , 
Anti-GDNF 
antibodies 
Headaches Headaches 
Reference [124] [126, 128] [129] [130] [138] [139] 
 
Abbreviations: rh recombinant human, MC Multi-centre, R Randomized, DB Double-blind, PC Placebo-
controlled, SSC Sham surgery-controlled, ICV Intracerebroventricular, IPu Intraputaminal, LS L’Hermitte’s sign 
 
 
